Efficacy, safety, and biomarker analysis of first-line immune checkpoint inhibitors with chemotherapy versus chemotherapy for advanced gastric cancer: a multicenter, retrospective cohort study

Abstract Background Recent phase III randomized controlled trials have demonstrated that first-line immune checkpoint inhibitors (ICIs) improve prognosis in advanced HER-2-negative gastric cancer patients with programmed death ligand 1 (PD-L1) combined positive score (CPS) higher than 5. However, th...

Full description

Bibliographic Details

Published in:	BMC Medicine
Main Authors:	Xue Zhang, Xin Dai, Aina Liu, Meili Sun, Lei Cong, Jing Liang, Zimin Liu, Zhen Li, Jinling Zhang, Jing Lv, Fangli Cao, Linli Qu, Haiyan Liu, Lu Yue, Yi Zhai, Fujun Yang, Jiahui Chu, Shuang Wang, Qian Xu, Jianyuan Zhou, Shulun Nie, Miao Huang, Ruitao Xu, Qiushi Wang, Xinyu Song, Di Zhang, Zhaodi Nan, Song Li, Lian Liu
Format:	Article
Language:	English
Published:	BMC 2024-12-01
Subjects:	Gastric cancer First-line treatment Immune checkpoint inhibitor Retrospective study Multi-omics
Online Access:	https://doi.org/10.1186/s12916-024-03801-5